Proposed combination of Tate & Lyle and CP Kelco to create a leading global speciality food and beverage solutions business

20 June 2024

Tate & Lyle PLC

(‘Tate & Lyle’)

Proposed combination of Tate & Lyle and CP Kelco to create
a leading global speciality food and beverage solutions business

Tate & Lyle announces that it has entered into an agreement to acquire the entire issued share capital of (i) CP Kelco U.S.; (ii) CP Kelco China; and (iii) CP Kelco ApS together with each of their respective subsidiaries (together ‘CP Kelco’), a leading provider of pectin, speciality gums and other nature-based ingredients, from J.M. Huber Corporation (‘Huber’) for a total implied consideration of US$1.8 billion (approximately £1.4 billion)¹, on a cash-free, debt-free basis (the ‘Proposed Transaction’).

Over the last six years, Tate & Lyle has been executing a major strategic transformation to become a growth-focused speciality food and beverage solutions business aligned to attractive structural and growing consumer trends for healthier, tastier and more sustainable food and drink. This transformation has included a much sharper focus on customers and key categories, increased investment in innovation and solution selling capabilities, and the significant strengthening of its Sweetening, Mouthfeel and Fortification platforms through new product development and acquisitions.  This transformation was completed with the announcement on 23 May 2024 of the proposed sale of Tate & Lyle’s remaining interest in Primary Products Investments LLC (‘Primient’).

The Proposed Transaction significantly accelerates Tate & Lyle’s strategy to be a leading and differentiated speciality food and beverage solutions business, and to become the solutions partner of choice for customers.  It is expected to drive stronger revenue growth and significant adjusted EBITDA margin improvement over the next few years.  It is also expected to be accretive to adjusted earnings per share, including cost synergies only, in the second full financial year following completion, and strongly accretive thereafter.

TRANSACTION HIGHLIGHTS

• Under the terms of the Proposed Transaction Tate & Lyle will acquire CP Kelco for total implied headline consideration at completion of US$1.8 billion (c.£1.4 billion)¹, subject to customary adjustments, consisting of:

• US$1.15 billion (c.£905 million)¹ in cash from new and existing debt facilities and cash resources.
• Issue of 75 million new Tate & Lyle ordinary shares² to Huber with an implied value of c.US$645 million³ (c.£510 million).
• Deferred consideration of up to 10 million additional Tate & Lyle ordinary shares² to be delivered to Huber approximately two years post-completion of the Proposed Transaction, subject to performance criteria⁴ based on Tate & Lyle’s share price.

• The total implied headline consideration represents⁵ 10x CP Kelco’s adjusted EBITDA for the year ended 31 December 2023 including run-rate cost synergies.
• The Proposed Transaction is expected to deliver significant synergies:

• Targeted run-rate cost synergies of at least US$50 million (£40 million)¹ by the end of the second full financial year post-completion.
• In addition, reflecting the strong complementarity of the two businesses, the combination is expected to generate revenue synergies of up to 10% of CP Kelco’s revenue over the medium term, underpinning the acceleration in top-line growth of the enlarged Tate & Lyle.

• Huber will become a long-term shareholder (c.16%)⁶ in Tate & Lyle following completion.  The potential for Huber to become a long-term shareholder and participate in the future value creation from the combination of the two businesses was central to unlocking a transaction. Huber will be entitled to appoint two non-executive directors to the Tate & Lyle Board subject to Huber maintaining certain minimum shareholding thresholds in Tate & Lyle.
• The Proposed Transaction is expected to complete in the fourth quarter of the 2024 calendar year.

STRATEGIC RATIONALE

• The Proposed Transaction combines two highly complementary businesses – Tate & Lyle, a leader in Sweetening, Mouthfeel and Fortification, and CP Kelco, a leader in pectin and speciality gums – to create a leading, global speciality food and beverage solutions business.
• Creates a leader in Mouthfeel, a critical driver of customer solutions, and strengthens Tate & Lyle’s expertise across its three core platforms of Sweetening, Mouthfeel and Fortification.
• The combined product portfolio, technical expertise and complementary category offering delivers a compelling customer proposition, significantly enhancing Tate & Lyle’s solutions capabilities and increasing the opportunity to benefit from growing global consumer demand for healthier, tastier and more sustainable food and drink.
• Expands Tate & Lyle’s offering in its large (US$19 billion⁷) and fast-growing (6% CAGR⁷)speciality food and beverage ingredients addressable market, and unlocks further growth opportunities in its core and adjacent markets.
• Accelerates R&D and innovation through the combination of world-class scientific, technical and applications expertise, driving the development of new plant-based ingredients and solutions.
• The combination is underpinned by a shared purpose, values and culture, and a mutual belief in Tate & Lyle’s commitment to science, solutions and society.

FINANCIAL EFFECTS

• The Proposed Transaction accelerates the delivery of Tate & Lyle’s strategy to create a higher growth business underpinned by an attractive financial algorithm, including: 

• Drive revenue growth towards higher-end of Tate & Lyle’s 4%-6% per annum ambition⁸:
  • Industry growth: Increasing consumer demand for healthier, tastier and more sustainable food and drink.
  • Broader offering: Accelerate growth from complementary portfolios, platforms and categories.
  • Stronger capabilities: Enhanced capabilities to increase innovation and solution selling to customers.
• Drive significant adjusted EBITDA margin improvement over the next few years:
  • Cost synergies: Targeted run-rate cost synergies of at least US$50 million (£40 million) over the two full financial years following completion.
  • Margin improvement: Phased recovery in profitability of CP Kelco.
  • Solution selling: Margin accretive solution selling from two or more years.
• Target to consistently exceed 75% free cash flow conversion⁹.

• The Proposed Transaction is expected to be accretive to adjusted earnings per share, including cost synergies only, in the second full financial year following completion, and strongly accretive thereafter.
• Return on invested capital (ROIC) expected to exceed Tate & Lyle’s weighted average cost of capital (WACC) in the fifth full year following completion.
• Targeted run-rate cost synergies of at least US$50 million (£40 million) by the end of the second full financial year following completion, with 50% – 60% (or c.US$25 million) of cost synergies to be realised by the end of the first full financial year following completion. The cost to deliver these synergies is estimated to be around US$75 million. There is also significant opportunity to accelerate revenue growth and, over the medium term, we are targeting revenue synergies of up to 10% of CP Kelco’s revenue.
• Net debt to EBITDA leverage anticipated to be approximately 2.3x¹⁰ at the financial year-end following completion, with strong cash generation thereafter.  Tate & Lyle remains within its 1.0x to 2.5x long-term target net debt to EBITDA leverage range with the capacity and flexibility for further investment.
• No change to Tate & Lyle’s existing approach to capital allocation and dividend policy; Tate & Lyle remains committed to maintaining a strong and efficient balance sheet.
• The recently announced US$270 million (c.£215 million) share buyback programme, previously to follow completion of the sale of the remaining interest in Primient, will start today.

COMMENTING ON THE COMBINATION:

Nick Hampton, Chief Executive, Tate & Lyle said:

“A combination with CP Kelco is the perfect fit with Tate & Lyle’s growth-focused strategy and purpose. It significantly strengthens our Sweetening, Mouthfeel and Fortification platforms, enhances our solutions capabilities across our four core categories, and unlocks new growth opportunities.  Together, we will have a compelling customer proposition.  With our leading portfolio of speciality ingredients and a world-class team of food science experts, we will be uniquely placed to provide our customers with the solutions they need to meet growing consumer demand for healthier, tastier and more sustainable food and drink.

We’ve been collaborating with CP Kelco on innovation projects for many years and are very aware of their excellent products and the outstanding capabilities of their people. We are excited about the opportunities the combination will create for customers across the world, and the opportunities for employees in both companies to develop their careers across a broader global business.

Following on from the announcement of the proposed sale of our remaining interest in Primient last month, the proposed combination with CP Kelco represents a significant acceleration of our growth-focused strategy.  It creates a leading, global speciality food and beverage solutions business, ideally placed to benefit from the structural trends towards more plant-based, clean-label and sustainable ingredients and solutions. The growth potential of the proposed combined business is significant and we look forward to the future with confidence and excitement.”

David Hearn, Chair, Tate & Lyle said:

“Today’s announcement represents a major acceleration in the delivery of Tate & Lyle’s growth-focused strategy and the Board is very excited about the opportunities ahead.  Our strong management team has all the right capabilities to drive significant value from this transaction for the benefit of our shareholders, customers and employees.  We are delighted that, looking ahead, Huber will become a new long-term shareholder in Tate & Lyle.  We look forward to welcoming their two new non-executive directors to our Board, and to working with them, and our other shareholders, to progress the enlarged company’s growth strategy.”

Didier Viala, President, CP Kelco said:

“We are delighted to be joining with Tate & Lyle to create a leading and differentiated speciality food and beverage solutions business.  CP Kelco and Tate & Lyle are both highly customer-focused businesses with a shared passion for science and innovation.  With our complementary portfolio and deep technical expertise, we will bring new value to our customers and new opportunities for our employees. This is an exciting time for our combined businesses.”

Gretchen W. McClain, President & CEO, J.M. Huber Corporation said:

“Together, Huber and Tate & Lyle are taking a bold and strategic move by creating a combined entity well-positioned with scale to be the driving force behind the future of food and wellness. Huber has been an excellent steward of CP Kelco for the past 20 years with a relentless pursuit to growing and creating value as a leading provider of nature-based, specialty ingredient solutions. This step unlocks the full value of CP Kelco and our long-term partnership as a shareholder in Tate & Lyle signifies Huber’s long-term desire to remain engaged in the attractive food and beverage market. Our collective rich histories and depth of experience combined with our shared purpose, values and commitment to our customers, employees, and communities will enhance future value for all stakeholders.”

STEPS TO COMPLETION

The Proposed Transaction constitutes a Class 1 transaction for Tate & Lyle under the UK Listing Rules and is, therefore, as at the date of this announcement, conditional on the approval of Tate & Lyle’s shareholders.  As indicated by the Financial Conduct Authority (‘FCA’), the UK Listing Rules are expected to change in the coming weeks, such that the requirement for a shareholder vote for a Class 1 transaction would no longer apply. The Proposed Transaction is not conditional on the approval of Huber’s shareholders. 

The Proposed Transaction is conditional on receipt of certain customary regulatory approvals.  It is expected to complete in the fourth quarter of the 2024 calendar year.

 

 

SHARE BUYBACK PROGRAMME

On 23 May 2024, Tate & Lyle announced the intention to return the net cash proceeds of US$270 million (c.£215 million) from the sale of its remaining interest in Primient to shareholders through an on-market share buyback programme.  Previously, this programme was due to start following completion of the Primient sale, but it will now start today.  We continue to expect completion of the Primient sale to occur before the end of July 2024.

––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––––

1. Based on GBP:USD foreign exchange rate of £1:$1.2723, as at 5pm BST on 19 June 2024.
2. Tate & Lyle shares are ordinary shares with a nominal value of 29 1/6 pence each.
3. Value of shares based on Tate & Lyle share price of 677.0p per share as at close of trading on 19 June 2024.
4. Deferred share consideration contingent on Tate & Lyle’s volume-weighted average price for the 30 trading days ending on and including the date that is two years following completion of the Proposed Transaction, with the full 10 million shares to be issued if Tate & Lyle’s share price over such period is at least £10, and no deferred share consideration will be payable if Tate & Lyle’s share price over such period is £8.50 or below.
5. Acquisition multiple calculated based on purchase price of US$1.8 billion, divided by adjusted EBITDA of US$131 million for the financial year ending 31 December 2023 (in accordance with US GAAP) and US$50 million of run-rate cost synergies.
6. Based on 401,694,461 shares in issue on 31 March 2024 and including the 75 million Tate & Lyle shares to be issued to Huber at completion of the Proposed Transaction.
7. Speciality ingredient market, market research data, Tate & Lyle and BCG analysis; estimate value growth 2022-26; CAGR is compound annual growth rate.
8. Multi-year ambition to 31 March 2028.
9. Free cash conversion calculated as: free cash flow before capital expenditure divided by adjusted EBITDA.
10. Leverage of 2.3x excludes the impact of any liability required to be recognised in relation to deferred share consideration.

 

 

 

PRESENTATION TO ANALYSTS AND INVESTORS TODAY

 

Presentation only

A presentation by Nick Hampton, Chief Executive, Tate & Lyle, and Dawn Allen, Chief Financial Officer, Tate & Lyle, will be available to view on our website from 07.00 (BST) today. To access the presentation, click here.  Please note that the Q&A will not be accessible via this link. 

 

Presentation and Q&A

The presentation will be live streamed at 08.30 (BST) and will then be followed by a live Q&A session with Nick Hampton, Chief Executive and Dawn Allen, Chief Financial Officer.   To view and listen to this video webcast and Q&A, click here.

Please note that only sell-side analysts and any pre-registered buy-side investors will be able to ask questions during the Q&A session. Sell-side analysts will be automatically pre-registered. To pre-register, please contact [email protected].

The archive version of the presentation with Q&A will be available within two hours of the end of the live broadcast. To access this version, click here.

 

The preceding summary should be read in conjunction with the full text of the announcement below.

The person responsible for arranging the release of this announcement on behalf of Tate & Lyle is Claire-Marie O’Grady, Company Secretary.

 

 

 

FOR FURTHER INFORMATION PLEASE CONTACT:

For Tate & Lyle PLC:

 

Investors and Analysts

Christopher Marsh, VP Investor Relations

Tel: Mobile: +44 (0) 7796 192 688

 

Media

Nick Hasell, FTI Consulting

Tel: Mobile: +44 (0) 7825 523 383

Tel: Office: +44 (0) 203 727 1340

[email protected]

 

About Tate & Lyle:

Supported by our 160-year history of ingredient innovation, we partner with customers to provide consumers with healthier and tastier choices when they eat and drink. We are proud that millions of people around the world consume products containing our ingredients every day.

Through our expertise in sweetening, fortification, and texture, we develop ingredient solutions which reduce sugar, calories, and fat, add fibre and protein, and provide texture and stability in categories including beverages, dairy, bakery, snacks, soups, sauces, and dressings.

We have more than 3,300 employees working in around 58 locations across 121 countries. Science, Solutions, Society is our brand promise and how we will achieve our purpose of Transforming Lives Through the Science of Food. By living our purpose we believe we can successfully grow our business and have a positive impact on society. We live our purpose in three ways, by supporting healthy living, building thriving communities and caring for our planet.

Tate & Lyle is listed on the London Stock Exchange under the symbol TATE.L. American Depositary Receipts trade under TATYY. In the year to 31 March 2024, Tate & Lyle revenue from continuing operations totalled £1.65 billion. For more information, please visit https://www.tateandlyle.com or follow Tate & Lyle on X(Twitter), LinkedIn, Facebook or YouTube.